Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in Granulomatosis with Polyangiitis: results from a single centre.

Abstract

Objective: Rituximab (RTX) is an anti-CD20 antibody used successfully in Granulomatosis with Polyangiitis (GPA) for induction and maintenance of remission. Our study aims to evaluate the long term efficacy and safety of chronic pre-emptive RTX therapy in GPA.